Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients

被引:7
作者
McHorney, Colleen A. [1 ]
Peterson, Eric D. [2 ]
Ashton, Veronica [3 ]
Laliberte, Francois [4 ]
Crivera, Concetta [3 ]
Germain, Guillaume [4 ]
Sheikh, Naveed [4 ]
Schein, Jeff [3 ]
Lefebvre, Patrick [4 ]
机构
[1] Evidera, Bethesda, MD USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] Janssen Sci Affairs LLC, Titusville, NJ USA
[4] Grp Anal Ltee, Montreal, PQ, Canada
关键词
Treatment adherence and compliance; Anticoagulants; Atrial fibrillation; Stroke; Bleeding; DAILY DOSING FREQUENCY; MEDICATION ADHERENCE; RIVAROXABAN; PREVENTION; DABIGATRAN; THERAPY; NONADHERENCE; MANAGEMENT; PHYSICIANS; WARFARIN;
D O I
10.1080/03007995.2018.1530205
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To estimate the real-world (RW) impact of adherence to once-daily (QD: rivaroxaban and edoxaban) and twice-daily (BID: apixaban and dabigatran) non-vitamin K antagonist (NOACs) on the risk of stroke and major bleeding (MB) among non-valvular atrial fibrillation (NVAF) patients. Methods: First, claims from the Optum Clinformatics Data Mart database (July 2012-December 2016) were analyzed. Adult NVAF patients with >= 2 NOAC dispensings (index date) were included. The relationship between NOAC adherence (proportion of days covered >= 80%) and stroke/MB 1-year post-index was evaluated using adjusted Cox proportional hazards models. Second, the natural logarithm of hazard ratios (HRs) was multiplied to a literature-derived mean adherence difference between QD and BID NOACs yielding stroke and MB rates. Third, these rates were multiplied by 1-year Kaplan-Meier rates of stroke and MB which yielded the number of strokes prevented and MBs caused. Annual cost savings were evaluated using literature-based stroke ($81,414/patient) and MB ($63,905/patient) cost estimates. Results: In total, 54,280 patients were included. HRs for adherent vs non-adherent patients were 0.67 (p < .001) for stroke and 1.09 (p = .179) for MB. The claims-derived 1-year Kaplan-Meier rates were 3.0% and 3.4% for strokes and MBs, respectively. For 100,000 AF patients, 64 strokes were prevented (p < .001), and a non-significant number of MBs (n = 15, p < .191) were caused by QD vs BID NOACs annually, which leads to cost savings estimated at $58 million for QD NOACs. Conclusion: QD NOACs prevented a significant number of strokes and caused no significant increase in MBs compared to BID NOACs, which leads to significant net cost savings for NVAF patients in the US.
引用
收藏
页码:653 / 660
页数:8
相关论文
共 50 条
[41]   Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea [J].
Bae, Hee-Joon ;
Heo, Ji Hoe ;
Jung, Keun-Hwa ;
Lee, Yong-Seok ;
Hong, Keun-Sik ;
Seo, Woo-Keun ;
Koo, Jaseong ;
Cha, Jae-Kwan ;
Lee, Mi Ji ;
Seo, Bo-Jeong ;
Kim, Young-Joo ;
Kang, Seongsik ;
Seok, Jinmi ;
Lee, Juneyoung ;
Chung, Chin-Sang .
PLOS ONE, 2018, 13 (11)
[42]   A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore [J].
Tiew, Wen Jun ;
Wong, Vivien L. X. ;
Tan, Vern Hsen ;
Tan, Yong Chuan ;
Lee, Elena M. S. .
ANNALS ACADEMY OF MEDICINE SINGAPORE, 2020, 49 (11) :838-847
[43]   Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan [J].
Amin, Alpesh ;
Keshishian, Allison ;
Vo, Lien ;
Zhang, Qisu ;
Dina, Oluwaseyi ;
Patel, Chad ;
Odell, Kevin ;
Trocio, Jeffrey .
JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (03) :244-253
[44]   Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Warfarin Among Patients With Non-Valvular Atrial Fibrillation and Diabetes: ARISTOPHANES Diabetes Subgroup Analysis [J].
Deitelzweig, Steve ;
Keshishian, Allison ;
Li Xiaoyan ;
Dhamane, Amol ;
Luo Xuemei ;
Balachander, Neeraja ;
Rosenblatt, Lisa ;
Mardekian, Jack ;
Pan Xianying ;
Nadkarni, Anagha ;
Di Fusco, Manuela ;
Garcia, Alessandra B. ;
Yuce, Huseyin ;
Lip, Gregory Y. .
CIRCULATION, 2018, 138
[45]   Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies [J].
Deitelzweig, S. ;
Farmer, C. ;
Luo, X. ;
Vo, L. ;
Li, X. ;
Hamilton, M. ;
Horblyuk, R. ;
Ashaye, A. .
CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (09) :1583-1594
[46]   Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences [J].
Waranugraha, Yoga ;
Rizal, Ardian ;
Syaban, Mokhamad Fahmi Rizki ;
Faratisha, Icha Farihah Deniyati ;
Erwan, Nabila Erina ;
Yunita, Khadijah Cahya .
EGYPTIAN HEART JOURNAL, 2021, 73 (01)
[47]   Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Non-Valvular Atrial Fibrillation Patients: Results of A Real-World Study in a Metropolitan Area of Northern Italy [J].
Crocetti, Emanuele ;
Cattaneo, Sarah ;
Bergamaschi, Walter ;
De Servi, Stefano ;
Russo, Antonio Giampiero .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
[48]   Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group [J].
Pharithi, Rebabonye B. ;
Ranganathan, Deepti ;
O'Brien, Jim ;
Egom, Emmanuel E. ;
Burke, Cathie ;
Ryan, Daniel ;
McAuliffe, Christine ;
Vaughan, Marguerite ;
Coughlan, Tara ;
Morrissey, Edwina ;
McHugh, John ;
Moore, David ;
Collins, Ronan .
IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 (01) :101-108
[49]   Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation [J].
Briere, Jean-Baptiste ;
Wu, Olivia ;
Bowrin, Kevin ;
Millier, Aurelie ;
Toumi, Mondher ;
Taieb, Vanessa ;
Levy, Pierre ;
Coleman, Craig, I .
CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (11) :1867-1872
[50]   Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis [J].
Lundqvist, Carina Blomstrom ;
Sjalander, Sara ;
Garcia Rodriguez, Luis A. ;
Akerborg, Orjan ;
Jin, Guanyi ;
Caleyachetty, Amrit ;
Huelsebeck, Maria ;
Bowrin, Kevin ;
Schaefer, Bernhard ;
Mahdessian, Hovsep ;
Hofmeister, Lucas ;
Levin, Lars-Ake .
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) :1085-1091